Stereotaxis, Inc.

STXS

HealthcareMedical - Instruments & SuppliesAMEX

$1.85

Market Cap: $180.33M

Stereotaxis, Inc. (STXS) Valuation Summary

Updated Apr 6, 2026 22:28

Model	Range	Fair Value	Upside
▸ Discounted Cash Flow
Revenue DCF 5Y	$0.05 – $1.03	$0.06	-97.1%
Revenue DCF 10Y	—	N/A	—
▸ Trading Multiples
EV/Revenue	$0.34 – $1.43	$0.55	-70.7%

Valuation History

DCF Analysis

Stereotaxis, Inc. (STXS) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$0.06

Market Price

$1.85

Upside / Downside

-96.8%

Verdict

Overvalued

Using a Revenue DCF model with operating margin convergence from -68.3% to a target of 13.3% over 5 years, discounted at a WACC of 8.7%, Stereotaxis, Inc. (STXS) has an intrinsic value of $0.06 per share (range: $0.05 – $1.03).

Key Assumptions

Current Operating Margin

-68.3%

Target Operating Margin

13.3%

WACC

8.7%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

2.8%

Target CapEx/Rev

6.0%

D&A/Revenue

2.5%

Tax Rate

21.0%

Operating margin fades linearly from the current level to the industry target over the 5-year projection. CapEx intensity fades from the historical average to a maintenance level (D&A × 1.5). Tax is only applied when operating income is positive (NOL shield).

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	41	26.9%	-52.0%	-21	-21	1	(1)	1	-23	-22
2027	54	30.2%	-35.6%	-19	-19	1	(2)	4	-23	-21
2028	52	-1.9%	-19.3%	-10	-10	1	(2)	-0	-11	-9
2029	51	-1.9%	-3.0%	-2	-2	1	(3)	-0	-3	-2
2030	50	-1.9%	13.3%	7	5	1	(3)	-0	4	3

Enterprise Value Bridge

Sum of PV(FCFF)-51

Terminal Value (Gordon Growth at 3.0%)70

PV of Terminal Value48

Enterprise Value-3

(–) Net Debt-8

Equity Value5

(÷) Shares Outstanding91

Fair Value per Share$0.06

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.3%	10.3%	13.3%	16.3%	19.3%
6.7%	$-0	$0	$0	$1	$1
7.7%	$-0	$-0	$0	$0	$1
8.7%	$-0	$-0	$0	$0	$0
9.7%	$-0	$-0	$-0	$0	$0
10.7%	$-0	$-0	$-0	$0	$0

Current price: $1.85. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 28.3% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$0.55

Market Price

$1.85

Upside / Downside

-70.2%

Verdict

Overvalued

Using the industry peer median EV/Revenue multiple (trailing + forward), Stereotaxis, Inc. (STXS) has a fair value of $0.55 based on 10 comparable companies in the Medical - Instruments & Supplies industry.

EV/Revenue Valuation — Medical - Instruments & Supplies

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Stereotaxis, Inc.STXS	168	5.0x	6.8x
CVRx, Inc.CVRX	238	3.8x	3.8x
Arcturus Therapeutics Holdings Inc.ARCT	234	0.4x	0.7x
OraSure Technologies, Inc.OSUR	213	2.0x	1.2x
NeoGenomics, Inc.NEO	208	0.7x	0.7x
Quanterix CorporationQTRX	169	1.3x	1.0x
Sagimet Biosciences Inc.SGMT	165	44.7x	—
Sanara MedTech Inc.SMTI	158	1.8x	3.0x
MDxHealth S.A.MDXH	105	1.6x	1.6x
Humacyte, Inc.HUMA	102	57.0x	8.5x
Exagen Inc.XGN	74	0.7x	0.7x
Industry Median		1.7x	1.2x
(*) Revenue		32	24
= Enterprise Value		55	29
(-) Net Debt		-8	-8
Equity Value		63	37
(/) Outstanding shares		91	91
Fair Price		$1	$0

Selected Fair Value (avg of trailing + forward)

$0.55

-70.2%

Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.

Model

Range

Fair Value

Upside

▸ Discounted Cash Flow

Revenue DCF 5Y

$0.05 – $1.03

$0.06

-97.1%

Revenue DCF 10Y

—

N/A

—

▸ Trading Multiples

EV/Revenue

$0.34 – $1.43

$0.55

-70.7%

DCF Analysis

Stereotaxis, Inc. (STXS) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$0.06

Market Price

$1.85

Upside / Downside

-96.8%

Verdict

Overvalued

Key Assumptions

Current Operating Margin

-68.3%

Target Operating Margin

13.3%

WACC

8.7%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

2.8%

Target CapEx/Rev

6.0%

D&A/Revenue

2.5%

Tax Rate

21.0%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	41	26.9%	-52.0%	-21	-21	1	(1)	1	-23	-22
2027	54	30.2%	-35.6%	-19	-19	1	(2)	4	-23	-21
2028	52	-1.9%	-19.3%	-10	-10	1	(2)	-0	-11	-9
2029	51	-1.9%	-3.0%	-2	-2	1	(3)	-0	-3	-2
2030	50	-1.9%	13.3%	7	5	1	(3)	-0	4	3

Enterprise Value Bridge

Sum of PV(FCFF)-51

Terminal Value (Gordon Growth at 3.0%)70

PV of Terminal Value48

Enterprise Value-3

(–) Net Debt-8

Equity Value5

(÷) Shares Outstanding91

Fair Value per Share$0.06

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.3%	10.3%	13.3%	16.3%	19.3%
6.7%	$-0	$0	$0	$1	$1
7.7%	$-0	$-0	$0	$0	$1
8.7%	$-0	$-0	$0	$0	$0
9.7%	$-0	$-0	$-0	$0	$0
10.7%	$-0	$-0	$-0	$0	$0

Current price: $1.85. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 28.3% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$0.55

Market Price

$1.85

Upside / Downside

-70.2%

Verdict

Overvalued

EV/Revenue Valuation — Medical - Instruments & Supplies

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Stereotaxis, Inc.STXS	168	5.0x	6.8x
CVRx, Inc.CVRX	238	3.8x	3.8x
Arcturus Therapeutics Holdings Inc.ARCT	234	0.4x	0.7x
OraSure Technologies, Inc.OSUR	213	2.0x	1.2x
NeoGenomics, Inc.NEO	208	0.7x	0.7x
Quanterix CorporationQTRX	169	1.3x	1.0x
Sagimet Biosciences Inc.SGMT	165	44.7x	—
Sanara MedTech Inc.SMTI	158	1.8x	3.0x
MDxHealth S.A.MDXH	105	1.6x	1.6x
Humacyte, Inc.HUMA	102	57.0x	8.5x
Exagen Inc.XGN	74	0.7x	0.7x
Industry Median		1.7x	1.2x
(*) Revenue		32	24
= Enterprise Value		55	29
(-) Net Debt		-8	-8
Equity Value		63	37
(/) Outstanding shares		91	91
Fair Price		$1	$0

Selected Fair Value (avg of trailing + forward)

$0.55

-70.2%